236 related articles for article (PubMed ID: 17541735)
1. A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles.
Martínez Gómez JM; Fischer S; Csaba N; Kündig TM; Merkle HP; Gander B; Johansen P
Pharm Res; 2007 Oct; 24(10):1927-35. PubMed ID: 17541735
[TBL] [Abstract][Full Text] [Related]
2. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.
San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS
Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572
[TBL] [Abstract][Full Text] [Related]
3. Co-delivery of ovalbumin and CpG motifs into microparticles protected sensitized mice from anaphylaxis.
San Román B; Irache JM; Gómez S; Gamazo C; Espuelas S
Int Arch Allergy Immunol; 2009; 149(2):111-8. PubMed ID: 19127067
[TBL] [Abstract][Full Text] [Related]
4. Diaminosulfide based polymer microparticles as cancer vaccine delivery systems.
Geary SM; Hu Q; Joshi VB; Bowden NB; Salem AK
J Control Release; 2015 Dec; 220(Pt B):682-90. PubMed ID: 26359124
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of a therapeutic treatment using gas-filled microbubble-associated phospholipase A2 in a mouse model of honeybee venom allergy.
Corthésy B; Lassus A; Terrettaz J; Tranquart F; Bioley G
Allergy; 2016 Jul; 71(7):957-66. PubMed ID: 26850222
[TBL] [Abstract][Full Text] [Related]
6. Development of a poly (lactic-co-glycolic acid) particle vaccine to protect against house dust mite induced allergy.
Joshi VB; Adamcakova-Dodd A; Jing X; Wongrakpanich A; Gibson-Corley KN; Thorne PS; Salem AK
AAPS J; 2014 Sep; 16(5):975-85. PubMed ID: 24981892
[TBL] [Abstract][Full Text] [Related]
7. Intralymphatic injections as a new administration route for allergen-specific immunotherapy.
Martínez-Gómez JM; Johansen P; Erdmann I; Senti G; Crameri R; Kündig TM
Int Arch Allergy Immunol; 2009; 150(1):59-65. PubMed ID: 19339803
[TBL] [Abstract][Full Text] [Related]
8. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation.
Wang Q; Tan MT; Keegan BP; Barry MA; Heffernan MJ
Biomaterials; 2014 Sep; 35(29):8385-93. PubMed ID: 24986256
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic immunization of mice with phospholipase A2-loaded gas-filled microbubbles is protective against Th2-mediated honeybee venom allergy.
Bioley G; Lassus A; Terrettaz J; Tranquart F; Corthésy B
Clin Exp Allergy; 2016 Jan; 46(1):153-62. PubMed ID: 25900397
[TBL] [Abstract][Full Text] [Related]
10. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.
Mohanan D; Slütter B; Henriksen-Lacey M; Jiskoot W; Bouwstra JA; Perrie Y; Kündig TM; Gander B; Johansen P
J Control Release; 2010 Nov; 147(3):342-9. PubMed ID: 20727926
[TBL] [Abstract][Full Text] [Related]
11. Modulation of allergic responses in mice by using biodegradable poly(lactide-co-glycolide) microspheres.
Jilek S; Walter E; Merkle HP; Corthésy B
J Allergy Clin Immunol; 2004 Oct; 114(4):943-50. PubMed ID: 15480340
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles.
Zhang XQ; Dahle CE; Weiner GJ; Salem AK
J Pharm Sci; 2007 Dec; 96(12):3283-92. PubMed ID: 17497736
[TBL] [Abstract][Full Text] [Related]
13. Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery.
Diwan M; Elamanchili P; Cao M; Samuel J
Curr Drug Deliv; 2004 Oct; 1(4):405-12. PubMed ID: 16305402
[TBL] [Abstract][Full Text] [Related]
14. Encapsulation of Ole e 1 in biodegradable microparticles induces Th1 response in mice: a potential vaccine for allergy.
Batanero E; Barral P; Villalba M; Rodríguez R
J Control Release; 2003 Oct; 92(3):395-8. PubMed ID: 14568420
[TBL] [Abstract][Full Text] [Related]
15. Induction of a balanced Th1/Th2 immune responses by co-delivery of PLGA/ovalbumin nanospheres and CpG ODNs/PEI-SWCNT nanoparticles as TLR9 agonist in BALB/c mice.
Ebrahimian M; Hashemi M; Maleki M; Abnous K; Hashemitabar G; Ramezani M; Haghparast A
Int J Pharm; 2016 Dec; 515(1-2):708-720. PubMed ID: 27989827
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy.
Johansen P; Senti G; Martinez Gomez JM; Storni T; von Beust BR; Wüthrich B; Bot A; Kündig TM
Clin Exp Allergy; 2005 Dec; 35(12):1591-8. PubMed ID: 16393325
[TBL] [Abstract][Full Text] [Related]
17. Allergen-derived long peptide immunotherapy down-regulates specific IgE response and protects from anaphylaxis.
von Garnier C; Astori M; Kettner A; Dufour N; Heusser C; Corradin G; Spertini F
Eur J Immunol; 2000 Jun; 30(6):1638-45. PubMed ID: 10898500
[TBL] [Abstract][Full Text] [Related]
18. Protamine nanoparticles with CpG-oligodeoxynucleotide prevent an allergen-induced Th2-response in BALB/c mice.
Pali-Schöll I; Szöllösi H; Starkl P; Scheicher B; Stremnitzer C; Hofmeister A; Roth-Walter F; Lukschal A; Diesner SC; Zimmer A; Jensen-Jarolim E
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):656-64. PubMed ID: 23523543
[TBL] [Abstract][Full Text] [Related]
19. Co-encapsulated CpG oligodeoxynucleotides and ovalbumin in PLGA microparticles; an in vitro and in vivo study.
San Román B; Gómez S; Irache JM; Espuelas S
J Pharm Pharm Sci; 2014; 17(4):541-53. PubMed ID: 25579433
[TBL] [Abstract][Full Text] [Related]
20. Allergen-loaded biodegradable poly(D,L-lactic-co-glycolic) acid nanoparticles down-regulate an ongoing Th2 response in the BALB/c mouse model.
Schöll I; Weissenböck A; Förster-Waldl E; Untersmayr E; Walter F; Willheim M; Boltz-Nitulescu G; Scheiner O; Gabor F; Jensen-Jarolim E
Clin Exp Allergy; 2004 Feb; 34(2):315-21. PubMed ID: 14987314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
